Actelion stops DUAL Opsumit study
This article was originally published in Scrip
Executive Summary
Actelion's Tracleer successor Opsumit (macitentan) looks set to fail in the additional indication of digital ulcers in patients with systemic sclerosis, given that one of its two pivotal trials in this indication has just been stopped for futility.